Compare Abbott Laboratories (ABT) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Invesco S&P 500 Momentum ETF — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Invesco S&P 500 Momentum ETF trades at $149.39. The key difference: Abbott Laboratories pays a 2.63% dividend while Invesco S&P 500 Momentum ETF pays none, and Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | SPMO | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $136.62 | $161.66 |
52-Week Low | $82.57 | $107.84 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
SPMO trades at $152.98, up 1.43% with neutral technical signals despite bullish moving averages. The ETF shows strong momentum performance with 7.5% June gains and 44.4% Q2 returns, heavily weighted toward technology stocks (55%) including AI beneficiaries. Recent institutional activity shows mixed positioning with several advisors increasing stakes while others reduced exposure.
Outlook remains constructive given AI-driven momentum strength, though elevated valuations and potential rotation risks warrant monitoring. The ETF's rules-based methodology targeting top S&P 500 momentum performers positions it for continued growth, but concentration in technology exposes it to sector-specific volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
